Total Payments
$56,393
2024 Payments
$5,542
Companies
84
Transactions
2,365
Medicare Patients
6,733
Medicare Billing
$461,304
Payment Breakdown by Category
Food & Beverage$48,702 (86.4%)
Gifts$2,774 (4.9%)
Other$1,763 (3.1%)
Education$1,654 (2.9%)
Consulting$1,500 (2.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $48,702 | 2,279 | 86.4% |
| Gift | $2,774 | 26 | 4.9% |
| Long term medical supply or device loan | $1,763 | 19 | 3.1% |
| Education | $1,654 | 40 | 2.9% |
| Consulting Fee | $1,500 | 1 | 2.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $8,667 | 184 | $0 (2024) |
| Gilead Sciences, Inc. | $5,025 | 173 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $4,119 | 183 | $0 (2024) |
| Amgen Inc. | $3,071 | 118 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $2,846 | 111 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $2,757 | 150 | $0 (2023) |
| Merck Sharp & Dohme LLC | $2,638 | 136 | $0 (2024) |
| PFIZER INC. | $2,289 | 141 | $0 (2024) |
| Lilly USA, LLC | $1,737 | 110 | $0 (2024) |
| Janssen Biotech, Inc. | $1,598 | 72 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,542 | 232 | Gilead Sciences, Inc. ($679.80) |
| 2023 | $5,913 | 244 | Novartis Pharmaceuticals Corporation ($662.22) |
| 2022 | $5,883 | 281 | Gilead Sciences, Inc. ($598.20) |
| 2021 | $7,052 | 291 | Novartis Pharmaceuticals Corporation ($1,281) |
| 2020 | $5,389 | 246 | Novartis Pharmaceuticals Corporation ($742.45) |
| 2019 | $7,771 | 360 | Novartis Pharmaceuticals Corporation ($1,269) |
| 2018 | $9,670 | 377 | Novartis Pharmaceuticals Corporation ($1,632) |
| 2017 | $9,174 | 334 | Novartis Pharmaceuticals Corporation ($2,082) |
All Payment Transactions
2,365 individual payment records from CMS Open Payments — Page 1 of 95
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $26.76 | General |
| Category: ONCOLOGY | ||||||
| 12/20/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $26.04 | General |
| 12/12/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $23.54 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/11/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $21.10 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $17.44 | General |
| Category: VACCINES | ||||||
| 12/09/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $16.79 | General |
| Category: Hematology | ||||||
| 12/07/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $21.78 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/06/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Respiratory | ||||||
| 12/05/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $31.34 | General |
| 12/05/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $29.17 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/04/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $18.85 | General |
| Category: Hematology/Oncology | ||||||
| 12/02/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $15.44 | General |
| Category: RESPIRATORY | ||||||
| 12/01/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Education | In-kind items and services | $99.95 | General |
| Category: Oncology | ||||||
| 11/29/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $21.10 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/25/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $20.34 | General |
| Category: Bone Health | ||||||
| 11/23/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $20.91 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $19.30 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/22/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $7.82 | General |
| Category: PAIN | ||||||
| 11/20/2024 | Incyte Corporation | PEMAZYRE (Drug), MONJUVI | Food and Beverage | Cash or cash equivalent | $19.28 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 11/15/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $20.65 | General |
| Category: Cardio-renal | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $23.25 | General |
| Category: Oncology | ||||||
| 11/13/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $16.79 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $29.39 | General |
| 11/06/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $21.96 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 734 | 1,282 | $118,943 | $65,733 |
| 2022 | 16 | 809 | 1,329 | $139,139 | $73,047 |
| 2021 | 21 | 3,766 | 6,962 | $401,368 | $207,246 |
| 2020 | 22 | 1,424 | 4,154 | $270,033 | $115,279 |
Total Patients
6,733
Total Services
13,727
Medicare Billing
$461,304
Procedure Codes
75
All Medicare Procedures & Services
75 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 125 | 333 | $48,717 | $26,782 | 55.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 50 | 94 | $19,369 | $9,893 | 51.1% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 88 | 181 | $16,538 | $8,996 | 54.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 46 | 46 | $9,660 | $6,749 | 69.9% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 41 | 41 | $4,100 | $3,108 | 75.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 104 | 179 | $2,425 | $1,504 | 62.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 39 | 40 | $2,000 | $1,407 | 70.3% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 29 | 34 | $2,359 | $1,177 | 49.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 11 | 11 | $1,998 | $1,145 | 57.3% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 17 | 17 | $2,276 | $1,068 | 46.9% |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | Office | 2023 | 34 | 34 | $1,449 | $1,003 | 69.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 15 | 18 | $1,619 | $840.63 | 51.9% |
| 96127 | Assessment of emotional or behavioral problems | Office | 2023 | 67 | 177 | $3,755 | $791.51 | 21.1% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 32 | 32 | $952.96 | $680.07 | 71.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 21 | 30 | $1,200 | $387.89 | 32.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 15 | 15 | $525.00 | $201.20 | 38.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 135 | 319 | $46,521 | $24,109 | 51.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 86 | 166 | $34,196 | $16,733 | 48.9% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 116 | 197 | $17,132 | $8,369 | 48.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 42 | 42 | $8,820 | $6,369 | 72.2% |
| 99497 | Advance care planning, first 30 minutes | Office | 2022 | 38 | 38 | $5,083 | $2,683 | 52.8% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 50 | 63 | $4,267 | $2,466 | 57.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 30 | 44 | $3,951 | $2,074 | 52.5% |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | Office | 2022 | 60 | 61 | $2,599 | $1,880 | 72.3% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 24 | 24 | $2,400 | $1,686 | 70.3% |
About Dr. William Cheung, M.D
Dr. William Cheung, M.D is a Hematology & Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1629031208.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William Cheung, M.D has received a total of $56,393 in payments from pharmaceutical and medical device companies, with $5,542 received in 2024. These payments were reported across 2,365 transactions from 84 companies. The most common payment nature is "Food and Beverage" ($48,702).
As a Medicare-enrolled provider, Cheung has provided services to 6,733 Medicare beneficiaries, totaling 13,727 services with total Medicare billing of $461,304. Data is available for 4 years (2020–2023), covering 75 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location New York, NY
- Active Since 04/06/2006
- Last Updated 02/24/2011
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1629031208
Products in Payments
- KISQALI (Drug) $4,757
- OPDIVO (Biological) $2,034
- KEYTRUDA (Biological) $1,809
- PDR001 (Drug) $1,567
- FARXIGA (Drug) $1,141
- JARDIANCE (Drug) $793.00
- GILOTRIF (Drug) $791.33
- TAGRISSO (Drug) $782.14
- Tymlos (Biological) $755.69
- Lenvima (Drug) $734.59
- Vemlidy (Drug) $715.98
- Ozempic (Drug) $686.14
- PRADAXA (Drug) $569.33
- BEVESPI AEROSPHERE (Drug) $550.42
- Doptelet (Drug) $545.17
- IBRANCE (Drug) $541.37
- Creon (Drug) $525.14
- CABOMETYX (Drug) $518.95
- NINLARO (Drug) $508.59
- TRULICITY (Drug) $499.86
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in New York
Jeffrey Zwicker, M.d, M.D
Hematology & Oncology — Payments: $1.2M
Hematology & Oncology $1.2M
Manuel Hidalgo Medina, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Ahmed Sawas, M.d, M.D
Hematology & Oncology — Payments: $807,524
Hematology & Oncology $807,524
Ruben Niesvizky, Md, MD
Hematology & Oncology — Payments: $734,512
Hematology & Oncology $734,512
Jeffrey Laurence, Md, MD
Hematology & Oncology — Payments: $706,018
Hematology & Oncology $706,018
Dr. Joshua Sabari, M.d, M.D
Hematology & Oncology — Payments: $603,205
Hematology & Oncology $603,205